Karin Przyklenk, Ph.D., director of the Wayne State University School of Medicine’s Cardiovascular Research Institute, has been named editor in chief of the Journal of Cardiovascular Pharmacology and Therapeutics.
“This is truly an honor for me, for the Cardiovascular Research Institute and for the School of Medicine, and I believe this invitation reflects the national and international recognition that the institute and its members have achieved in the cardiovascular field,” said Dr. Przyklenk, a professor of Physiology and of Emergency Medicine.
Published four times a year, the peer-reviewed journal publishes original basic human studies, animal studies and bench research with potential clinical application to cardiovascular pharmacology and therapeutics. Dr. Przyklenk described the publication as “a well-respected mid-tier journal focused on translational cardiovascular research.”
She will serve as editor in chief for three years, with the possibility of two additional automatic two-year renewals.
Dr. Przyklenk said that three “outstanding colleagues” have agreed to join her and serve as associate editors: Peter Whittaker, Ph.D., professor of Emergency Medicine at the Wayne State University School of Medicine and member of the Cardiovascular Research Institute; Richard Vander Heide, M.D., Ph.D., professor and chair of Pathology at Louisiana State University and a former professor of Pathology at WSU; and Bruno Podesser, M.D., professor of Animal Research and Cardiac Surgery, and head of the Center for Biomedical Research at the Medical University of Vienna (Austria).
“All three associate editors are distinguished cardiovascular scientists and bring distinct areas of expertise to the journal,” she said. “I believe we will make an outstanding editorial team.”
Dr. Przyklenk’s goals for the journal include expanding the scope and impact within its established niche of translational cardiovascular pharmacology and cardio-protection; increasing the number of citations of articles published in the journal to increase its impact factor; increasing the visibility and profile of the journal by establishing a presence at relevant cardiovascular conferences and meetings; offering annual awards for “best publication by a young investigator” in basic, translational and clinical categories, and creating “Outstanding Reviewer” awards; expanding awareness through social media; and broadening the publication’s scope from its current emphasis on in-vivo preclinical and clinical studies to encompass high-quality cardiovascular epidemiologic studies, meta-analyses and cost-effectiveness studies.